Novartis Terminates Combination Therapies, Studies With Rasilez/Tekturna - NASDAQ PDF Print
NASDAQ
(RTTNews.com) - Novartis AG (NVS) Tuesday said it has terminated ALTITUDE study with Rasilez/Tekturna in high-risk patients with diabetes and renal impairment, as an independent data monitoring committee identified higher adverse events in patients ...
Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.